Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-18-064090
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-12-26 16:15:49
Reporting Period:
2018-12-20
Accepted Time:
2018-12-26 16:15:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1339970 Atyr Pharma Inc LIFE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1238362 John Mendlein 3545 John Hopkins Court, Suite 250
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-12-20 50,000 $0.41 420,382 No 4 P Direct
Common Stock Acquisiton 2018-12-21 195,000 $0.42 615,382 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Footnotes
  1. Represents weighted average price for the shares. The shares were purchased at price ranging from $0.4013 to $0.4100 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
  2. Represents weighted average price for the shares. The shares were purchased at price ranging from $0.4048 to $0.4300 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.